Comparative Pharmacology
Head-to-head clinical analysis: AMINO ACIDS versus TRAVASOL 3 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
Head-to-head clinical analysis: AMINO ACIDS versus TRAVASOL 3 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
AMINO ACIDS vs TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES is a parenteral nutrition solution providing amino acids, electrolytes, and calories (as dextrose). Amino acids are used for protein synthesis, and electrolytes maintain acid-base balance and osmotic pressure.
1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.
Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 mL/kg/hour, adjusted to meet metabolic needs. Typical adult daily dose: 0.8-1.5 g amino acids/kg/day, equivalent to 23-43 mL/kg/day of TRAVASOL 3.5%.
None Documented
None Documented
Variable; endogenous amino acids: 10–30 min for clearance from plasma; administered doses: distribution half-life ~5–10 min, terminal elimination half-life ~15–30 min, reflecting rapid metabolic utilization and renal reabsorption.
Not applicable as a fixed half-life; amino acids have rapid plasma clearance (t1/2 of 10-30 minutes for individual amino acids). Clinical context: Continuous infusion maintains steady state.
Renal: >95% as amino acids and metabolites, primarily reabsorbed; <5% unchanged. Fecal/biliary: negligible (<1%).
Renal: >95% of infused amino acids and electrolytes are excreted unchanged or as metabolites. Biliary/fecal: <5%.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution